Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (Zelboraf®)

NCT01990248 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01990248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01990248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (Zelboraf®)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
March 23, 2013
Completion date
July 26, 2016
Enrollment
339 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma